These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 1881245)

  • 1. Iron oxide nanoparticles for use as an MRI contrast agent: pharmacokinetics and metabolism.
    Pouliquen D; Le Jeune JJ; Perdrisot R; Ermias A; Jallet P
    Magn Reson Imaging; 1991; 9(3):275-83. PubMed ID: 1881245
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biodegradation of magnetite dextran nanoparticles in the rat. A histologic and biophysical study.
    Okon E; Pouliquen D; Okon P; Kovaleva ZV; Stepanova TP; Lavit SG; Kudryavtsev BN; Jallet P
    Lab Invest; 1994 Dec; 71(6):895-903. PubMed ID: 7807971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatic cellular distribution and degradation of iron oxide nanoparticles following single intravenous injection in rats: implications for magnetic resonance imaging.
    Briley-Saebo K; Bjørnerud A; Grant D; Ahlstrom H; Berg T; Kindberg GM
    Cell Tissue Res; 2004 Jun; 316(3):315-23. PubMed ID: 15103550
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of superparamagnetic iron-oxide MR contrast agents in the rat.
    Majumdar S; Zoghbi SS; Gore JC
    Invest Radiol; 1990 Jul; 25(7):771-7. PubMed ID: 2391194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liver-directed superparamagnetic iron oxide: quantitation of T2 relaxation effects.
    Pouliquen D; Lucet I; Chouly C; Perdrisot R; Le Jeune JJ; Jallet P
    Magn Reson Imaging; 1993; 11(2):219-28. PubMed ID: 8455432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Superparamagnetic iron oxide nanoparticles as a liver MRI contrast agent: contribution of microencapsulation to improved biodistribution.
    Pouliquen D; Perdrisot R; Ermias A; Akoka S; Jallet P; Le Jeune JJ
    Magn Reson Imaging; 1989; 7(6):619-27. PubMed ID: 2630844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic and hemodynamic safety of two superparamagnetic agents, Endorem and Sinerem, in cirrhotic rats.
    Bonnemain B
    Acad Radiol; 1998 Apr; 5 Suppl 1():S151-3; discussion S156. PubMed ID: 9561067
    [No Abstract]   [Full Text] [Related]  

  • 8. Superparamagnetic iron oxide: pharmacokinetics and toxicity.
    Weissleder R; Stark DD; Engelstad BL; Bacon BR; Compton CC; White DL; Jacobs P; Lewis J
    AJR Am J Roentgenol; 1989 Jan; 152(1):167-73. PubMed ID: 2783272
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liver tumors in cirrhosis: experimental study with SPIO-enhanced MR imaging.
    Clement O; Frija G; Chambon C; Schouman-Clayes E; Mosnier JF; Poupon MF; Balkau B
    Radiology; 1991 Jul; 180(1):31-6. PubMed ID: 2052718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distribution of iron oxide nanoparticles in rat lymph nodes studied using electron energy loss spectroscopy (EELS) and electron spectroscopic imaging (ESI).
    Bordat C; Sich M; Réty F; Bouet O; Cournot G; Cuénod CA; Clément O
    J Magn Reson Imaging; 2000 Sep; 12(3):505-9. PubMed ID: 10992320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The pharmacokinetics of the lymphotropic nanoparticle MRI contrast agent ferumoxtran-10.
    Islam T; Wolf G
    Cancer Biomark; 2009; 5(2):69-73. PubMed ID: 19414923
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biodistribution of ultrasmall iron oxide particles in the rat liver.
    Van Beers BE; Sempoux C; Materne R; Delos M; Smith AM
    J Magn Reson Imaging; 2001 Apr; 13(4):594-9. PubMed ID: 11276104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biodistribution of an ultrasmall superparamagnetic iron oxide colloid, BMS 180549, by different routes of administration.
    Bengele HH; Palmacci S; Rogers J; Jung CW; Crenshaw J; Josephson L
    Magn Reson Imaging; 1994; 12(3):433-42. PubMed ID: 8007773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atorvastatin and uptake of ultrasmall superparamagnetic iron oxide nanoparticles (Ferumoxtran-10) in human monocyte-macrophages: implications for magnetic resonance imaging.
    Müller K; Skepper JN; Tang TY; Graves MJ; Patterson AJ; Corot C; Lancelot E; Thompson PW; Brown AP; Gillard JH
    Biomaterials; 2008 Jun; 29(17):2656-62. PubMed ID: 18377983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Electron microscopy study of intrahepatic ultrasmall superparamagnetic iron oxide kinetics in the rat. Relation with magnetic resonance imaging.
    Dupas B; Berreur M; Rohanizadeh R; Bonnemain B; Meflah K; Pradal G
    Biol Cell; 1999 Jun; 91(3):195-208. PubMed ID: 10425706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term imaging effects in rat liver after a single injection of an iron oxide nanoparticle based MR contrast agent.
    Briley-Saebø K; Hustvedt SO; Haldorsen A; Bjørnerud A
    J Magn Reson Imaging; 2004 Oct; 20(4):622-31. PubMed ID: 15390223
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clearance of iron oxide particles in rat liver: effect of hydrated particle size and coating material on liver metabolism.
    Briley-Saebo KC; Johansson LO; Hustvedt SO; Haldorsen AG; Bjørnerud A; Fayad ZA; Ahlstrom HK
    Invest Radiol; 2006 Jul; 41(7):560-71. PubMed ID: 16772849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MRI detection of macrophages labeled using micrometer-sized iron oxide particles.
    Williams JB; Ye Q; Hitchens TK; Kaufman CL; Ho C
    J Magn Reson Imaging; 2007 Jun; 25(6):1210-8. PubMed ID: 17520727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Localization to atherosclerotic plaque and biodistribution of biochemically derivatized superparamagnetic iron oxide nanoparticles (SPIONs) contrast particles for magnetic resonance imaging (MRI).
    Smith BR; Heverhagen J; Knopp M; Schmalbrock P; Shapiro J; Shiomi M; Moldovan NI; Ferrari M; Lee SC
    Biomed Microdevices; 2007 Oct; 9(5):719-27. PubMed ID: 17562181
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of resovist on rats with different severities of liver cirrhosis.
    Kato N; Ihara S; Tsujimoto T; Miyazawa T
    Invest Radiol; 2002 May; 37(5):292-8. PubMed ID: 11979155
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.